Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-11
2010-11-02
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S217000, C514S321000, C514S557000, C514S649000, C424S610000
Reexamination Certificate
active
07825156
ABSTRACT:
A benzamide derivative, especially amisulpride, is used to prevent or treat bipolar depression of a patient suffering from bipolar disorder I or bipolar disorder II.
REFERENCES:
patent: 4401822 (1983-08-01), Thominet et al.
patent: 6187807 (2001-02-01), Perrault et al.
patent: 2003/0130334 (2003-07-01), Muller
Aetna InteliHealth (intelihealth.com [online], www.intelihealth.com, Jul. 2006 [retrieved on Dec. 12, 2008]. Retrieved from the Internet: <URL: http://www.intelihealth.com/IH/ihtIH/WSIHW000/9339/9803.html.).
Science Daily ([online], www.sciencedaily.com, Jul. 2005 [retrieved Dec. 12, 2008]. Retrieved from the Internet: <URL: http://www.sciencedaily.com/releases/2005/07/050704114242.htm).
Manzaneque et al. (Aggressive Behavior, vol. 25, pp. 225-232; 1999).
Galinsky et al. [“Basic Pharmacokinetics and Pharmacodynamics.” in: Remington: The Science and Practice of Pharmacy (Baltimore, Lippincott Williams & Wilkins, 2006), p. 1171].
Patani et al. (Chem Rev, vol. 96, No. 8, pp. 3147-3176; 1996).
“Improvement of Schizophrenic Patients with Primary Negative Symptoms Treated with Amisulpride” Jean-Marie Danion, M.D. et al. Am J Psychiatry 156:4, Apr. 1999: 610-616.
“An Open Label Follow-Up Study on Amisulpride in the add-On Treatment of Bioplar I Patients” Mauro Giovanni Carta et al. Clinical practice and Epidemiology in Mental Health 2006, 2:19.
Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity. H. Schoemaker et al. The Journal of Pharmacology and Experimental Therapeutics 1997, 280/1:83-97.
“Amisulpride Versus Placebo in the Medium-Term Treatment of the Negative Symptoms of Schizophrenia” H.Loo et al. Br J Psychiatry 1999, 170:18-22.
Copharms
Dickstein & Shapiro LLP
Henley, III Raymond J
LandOfFree
Method of treating bipolar depression with a benzamide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating bipolar depression with a benzamide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating bipolar depression with a benzamide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190337